Physician profile
Gregory Kw Lam
NPI 1255319760
$428,422.86
in general payments reported to CMS, 2019-2025
16 companies · $37K in 2025
The $37K reported for 2025 was more than what 98% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83K · 2020: $68K · 2021: $68K · 2022: $71K · 2023: $56K · 2024: $46K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Food and Beverage: $2,994 · Travel and Lodging: $2,028 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $133,710.00 |
| Food and Beverage | $2,994.35 |
| Travel and Lodging | $2,028.04 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $248,726.06 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $167,709.66 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $10,472.33 | 2019 | |
| Novo Nordisk INC | $337.15 | 2022-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $257.68 | 2020-2025 | |
| Capsopro Services LLC | $200.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $196.48 | 2025 | |
| Boston Scientific Corporation | $111.22 | 2019-2020 | |
| Pfizer INC. | $101.57 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.16 | 2021-2024 | Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $65.59 | 2020-2023 | Xifaxan |
| Abbott Laboratories | $40.12 | 2025 | Cardiomems |
| Amgen INC. | $36.21 | 2022-2024 | Repatha |
| Shire North American Group INC | $32.44 | 2019 | |
| Medtronic, INC. | $23.02 | 2025 | Linq II |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $13.17 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.